Bioscience – Groundbreaking Research & Diagnostics: Gothenburg 2026

Join us at SLAS Barcelona

Festo LifeTech is exhibiting at the SLAS in Barcelona.

Danish biotech to buy struggling American oncology company

Danish drugmaker Pharmacosmos has agreed to acquire American pharmaceutical company G1 Therapeutics in a deal that amounts to 405 million dollars.

Xbrane enters licensing agreement with Indian generics giant

Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.

ZEISS Metrology Shop provides planning security

ZEISS Metrology Shop brings it all together.

600 million SEK for life science - "Should not be the country of moderation"

Sweden will prioritize excellence over breadth in research. This was made clear when the government presented the research proposition for the next four years.

About Microscope Ergonomics

Learn about ergonomic microscope design and how you can increase your well-being and productivity when working in clinical microscopy. Read about challenges, de...

Quretech granted a European patent for a new type of antibiotic

The European patent provides protection until 2041. Previously, the patent was granted in China, and the application is currently under review in the USA, India, and Japan.

New large lab building in Lund inaugurated – here are the companies moving in

Medicon Village has received a new laboratory building. On Friday last week the building was inaugurated with a ribbon-cutting ceremony by Minister for Employme...

Topp 20-listor: Sveriges främsta forskare inom molekylär- och mikrobiologi

Mathias Uhlén, Staffan Normark, Joakim Dillner och Carl-Henrik Heldin är namnen som återfinns högst på listorna över Sveriges mest citerade forskare inom mikrob...

Her company is developing a new tablet form obesity drug

Obesity and diabetes are the primary targets of a new tablet treatment under development by Malmö-based Pila Pharma. The company’s ambition is to take on the bi...

Topp 20-listor: Här är främsta forskarna inom immunologi och genetik

Lars Klareskog och Tomas Olsson vid Karolinska institutet rankas som Sveriges främsta forskare inom immunologi. Juha Kere, också Karolinska, är etta på listan ö...

Don't miss ZEISS Quality Innovation Days

Digital event April 15-19, 2024.

Innovative start-up helps doctors, scientists and industry balance coagulation risks

For many doctors caring for seriously ill patients, for example, in stroke units and cancer wards, maintaining the life-saving balance between bleeding and thro...

Advancing 3D Culture Imaging: Insights from Academia, Biotech, and Pharma

Webinar | March 13, 2024, 12 PM EST.

In search of Marcel Proust's lost health

A great writer, but also a weak person and a hypochondriac. That has been the usual image of Marcel Proust. But the pediatrician and literary scholar Carl Lindg...

Stockholm and Uppsala jointly form a life science cluster

Stockholm and Uppsala are strengthening cooperation in medical research and biotech.

This years Nobel prize in medicine – “Changed the understanding of how genes are controlled”

This year’s Nobel Prize in Physiology or Medicine goes to the discovery that small RNA molecules, known as microRNAs, control how genes are regulated. Understan...

Improve your secondary battery manufacturing

SMC provides a large portfolio of products specially designed for secondary battery industry.

ZEISS Quality Innovation Days: April 15 – 19, 2024

Be there when industry experts give exciting insights into different applications and trends in 90 minutes on various theme days.

Glatt besked för Lundabolag – Europapatent på väg att beviljas

Synact Pharma kommer att beviljas europeiskt patent för den kliniska formuleringen av Resomelagon, enligt ett förhandsbesked till företaget.

Vd-skifte på Hamlet Biopharma

Hamlet Biopharma utser tidigare styrelseordföranden Catharina Svanborg till ny vd. Hon ersätter Martin Erixon som lämnar bolaget med omedelbar verkan.

Anna Törner: The clinical trial – Periscope to reality

What happens to the patients in the clinical trial is not very interesting, writes Anna Törner in a column.

“Don’t postpone the transition to IVDR”

Operators who have not yet started to adapt to the requirements of the new EU IVDR regulation are running out of excuses. This is the opinion of Helena Dzojic, ...